Cardiovascular Disease Doctors in Pine Bluff, AR Accepting Medicare

5 Cardiovascular Disease doctors found. Showing 1 - 5

Dr. Sadeem Mahmood, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7200 S Hazel St, Pine Bluff, AR 71603 Phone: 870-534-2900    Fax: 870-534-9726

Faiz Ur Rehman, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7200 S Hazel St, Pine Bluff, AR 71603 Phone: 870-534-2900

Nicholas Willis, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1601 W 40th Ave, Suite 301, Pine Bluff, AR 71603 Phone: 870-541-4285    Fax: 870-541-4297

Shabbir Dharamsey, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7200 S Hazel St, Pine Bluff, AR 71603 Phone: 870-534-2900    Fax: 870-534-2900

Dr. Ricki Yvonne Fram, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1601 W 40th Ave, Suite 301, Pine Bluff, AR 71603 Phone: 870-541-4285    Fax: 870-541-4297

News Archive

Study shows high-risk drinking may improve post weight loss surgery

Much has been reported about the potential for increased risk of alcohol misuse after weight loss surgery (WLS), with most theories pointing to lower alcohol tolerance and a longer time to return to a sober state after surgery, but a new study from Beth Israel Deaconess Medical Center suggests that upwards of half of high-risk drinkers are actually less likely to report high-risk drinking behavior after weight loss surgery.

PerkinElmer Genetics launches new Lysosomal Storage Disorder panel

PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, announced today that its newborn screening laboratory service, PerkinElmer Genetics, has launched a new panel to screen for six Lysosomal Storage Disorders (LSDs) as an addition to its current newborn testing and diagnostics portfolio.

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV).

Breakthrough discovery could open up new treatments for some blood cancers

Reversing runaway inflammation in the bone marrow could lead to major breakthroughs in treatments for some blood cancers, according to a new publication by scientists at Hackensack Meridian Health's Center for Discovery and Innovation.

Read more Medical News

› Verified 6 days ago